Based on the anti-angiogenic potency of FSCN1 knockdown observed in our data, we anticipate that NP-G2-044 may function not only as an anti-metastatic drug for malignant tumors but also as a promising drug for pathological ocular neovascularization. This evidence concerns the gene FSCN1 and cancer.